CD44 targeting polypeptide and application thereof for preparing affinitive probe used for screening early gastric cancer

An early gastric cancer, targeted technology, applied in the fields of peptides, material testing products, biological testing, etc., can solve the problems of conventional gastroscopic diagnosis and treatment technology defects, low gastric cancer diagnosis rate, high misdiagnosis rate, and achieve high clinical application value and efficient screening. Check the effect

CN104327161AActive Publication Date: 2015-02-04赛特斯(海南)生物医学有限公司
5 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2015-02-04

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a CD44 targeting polypeptide and an application thereof for preparing an affinitive probe used for screening early gastric cancer. The polypeptide includes an amino acid sequence of WHPWSY. The polypeptide can be specifically combined with a gastric cancer bio-labeled molecule CD44 and can be used as the affinitive probe with a common optical endoscope or a con-focal fluorescent micro-endoscope for achieving high-efficient screening of the gastric cancer. The CD44 targeting polypeptide overcomes a defect that only a random multi-point biopsy method can be employed in detection of a large-area gastric mucosa suspected lesion by a conventional optical endoscope. The CD44 targeting polypeptide can achieve early-stage, real-time and localized diagnosis in gastroscopy and is high in clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a polypeptide reagent for early diagnosis of gastric cancer realized by molecular imaging under an endoscope, in particular to a CD44 targeting polypeptide and its application in the preparation of an affinity probe for screening early gastric cancer. Background technique

[0002] (1) Dilemma of early diagnosis of gastric cancer

[0003] Gastric cancer patients in my country generally have a late stage of disease when they receive treatment, and the 5-year survival rate is only about 30%, while the overall survival rate of patients with early gastric cancer (EGC) is as high as 90%, and the 10-year recurrence rate is only 2- 3%, so early detection and early treatment are the key to improving the efficacy of gastric cancer. However, except for Japan and South Korea, where a relatively large proportion of early gastric cancers were discovered due to the national gastric cancer endoscopic screening, the detection rate of early gast...

Examples

Embodiment Construction

[0029]The present invention will be described in detail below in conjunction with the accompanying drawings and embodiments.

[0030] (1) Using phage display peptide library technology, the CD44-specific 12-peptide WHPWSYLWTQQA (Trp His Pro Trp Ser Tyr Leu Trp Thr Gln Gln Ala).

[0031] The 12 peptides in ELISA (see figure 1 ), cell immunofluorescence experiments (see figure 2 ) all showed good specificity and affinity for CD44. Since the hexapeptide motif WHPWSY was also found in another specific polypeptide sequence for CD44 screened out, it is speculated that the 12 peptides may be obtained through the hexapeptide motif WHPWSY Binds to CD44, therefore, using software for both (Molegro Virtual Docker,

[0032] LigPlus) carried out molecular docking, and the results showed that the two have good binding characteristics in configuration and energy (see image 3 and Table 1).

[0033] Depend on figure 1 It can be seen that the phage displaying the polypeptide WHPWSYLWTQQ...